Skip to content
Review Open access

Memory, social cognition, and beyond: Neuropsychological markers differentiating Alzheimer's disease and frontotemporal dementia

Sep 2026 · Journal of Alzheimer's Disease · Vol 113, pp. 1570 - 1586 · 0 citations · 95 references
Medicine

TL;DR

Differentiation between AD and FTD should not rely on single cognitive domains; the most clinically meaningful distinction is achieved through a multidimensional assessment integrating episodic memory, social cognition, and selected executive and behavioral measures.

Abstract

Background Distinguishing Alzheimer's disease (AD) from frontotemporal dementia (FTD) remains a major clinical challenge, particularly in early disease stages due to overlapping symptoms. Although neuropsychological assessment is central to diagnosis, brief cognitive screening instruments often emphasize episodic memory, whereas comprehensive neuropsychological assessment encompasses multiple cognitive domains. Nevertheless, social cognition and other relevant functions may remain underrepresented in routine clinical assessment. Objective To identify neuropsychological domains and test procedures that reliably differentiate AD from FTD and support differential diagnosis. Methods A systematic PubMed literature search was conducted using predefined inclusion and exclusion criteria. Original studies directly comparing neuropsychological performance in patients with AD and FTD were included. Owing to methodological heterogeneity, findings were synthesized narratively. Results A total of 322 records were identified, of which 80 studies met the inclusion criteria. A clear domain-specific pattern emerged. Episodic memory impairment, particularly delayed recall deficits, consistently distinguished AD from FTD, with poorer performance in AD. In contrast, deficits in social cognition, including theory of mind and emotion recognition, were more pronounced in FTD and were often detectable early in the disease course. Executive functions and language showed heterogeneous findings, with discriminative value depending on specific subdomains and FTD subtypes. Visuospatial functions and attention provided supportive but less consistent differentiation, while global screening instruments showed limited diagnostic specificity. Conclusions Differentiation between AD and FTD should not rely on single cognitive domains. The most clinically meaningful distinction is achieved through a multidimensional assessment integrating episodic memory, social cognition, and selected executive and behavioral measures.

Read PDF

Similar papers

Sep 2026

Recognition memory as a neuropsychological marker of progression in early-stage Alzheimer's disease: a 24-month prospective cohort study.

SDT-derived recognition indices, especially d'prime, provide clinically relevant prognostic information in a-MCI and adding d' to delayed recall and biomarkers may improve risk stratification, follow-up planning, and selection for disease-modifying trials.

María Julieta Russo, José Bueri, L. Alba-Ferrara et al. · 0 citations
Sep 2026

Functional hearing difficulty in Alzheimer's disease: Selective links to verbal fluency and behavioral and psychological symptoms of dementia severity.

BackgroundHearing loss is a well-established risk factor for dementia. However, the clinical relevance of everyday listening difficulties after the diagnosis of Alzheimer's disease (AD) remains insufficiently understood, particularly in relation to cognition and behavioral and psychological symptoms of dementia (BPSD)....

M. Uchiyama, Takuya Sato, Y. Mamiya et al. · 0 citations
Review Open access 2026

Subjective Cognitive Decline as a Preclinical Marker of Dementia: A Theoretical Review and Conceptual Framework of Longitudinal Studies in Older Adults

The need for standardized diagnostic criteria and integrative models that encompass the clinical, biological, cognitive, and psychosocial domains to enhance the predictive and diagnostic value of SCD in the context of neurodegenerative disease is underscored.

V. Pérez, Daniela Batallas, V. Hidalgo et al. · 0 citations
Review Open access Aug 2026

The Famous Faces Test: A Systematic Review of Its Design and Potential for Detecting Early Alzheimer's Disease.

ObjectiveEarly Alzheimer's disease (AD) is currently diagnosed using costly and invasive biomarkers. The Famous Faces Test (FFT) may detect (subtle) cognitive impairment earlier than standard neuropsychological tests. This review aimed to identify methodological variation across FFTs and evaluate their ability to detec...

Ruth E. Mark, Daphne M. Tabak, Demi van den Ende et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.